What retatrutide is, how it differs from semaglutide and tirzepatide, what the trials showed, the side effects, and why it is still not approved.
45 min read
Retatrutide is an investigational once-weekly injectable from Eli Lilly that activates three metabolic receptors at once: GLP-1, GIP and glucagon. It has produced the largest average weight-loss figures reported for any single agent, and that has made it one of the most searched and most misunderstood compounds online. This guide separates what the trials actually measured from what the internet assumes, tags every claim with its evidence level, and is clear about the point that matters most: retatrutide is not an approved medicine anywhere.
What's Inside
Written for adults who keep hearing about retatrutide and want to understand what it is, what the trials showed and what is still unknown before forming an opinion. It suits people already using semaglutide or tirzepatide under medical care, coaches fielding questions about it, and anyone comparing the options. It is not a protocol, it is not a source, and it cannot replace a clinician or a clinical trial.
Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GIP and GLP-1. Retatrutide adds a third, the glucagon receptor, which makes it a triple agonist rather than a stronger version of either. The GLP-1 arm slows gastric emptying and drives satiety, the GIP arm amplifies the insulin response and may improve tolerability, and the glucagon arm works on the liver, mobilising hepatic fat and raising energy expenditure. On its own, glucagon would push blood glucose up; the design relies on the GLP-1 and GIP signals holding glucose in check while the glucagon arm does its metabolic work. Retatrutide is also slow-onset and slow-offset, with a half-life of about six days, so exposure keeps building for weeks after any change. That is why titration exists, and why rushing it stacks exposure and drives the worst nausea and vomiting.
More than on any single agent tested so far, with important caveats. In the Phase 2 obesity trial, the highest dose studied produced an average weight loss of about 24 percent at 48 weeks, with no plateau yet reached, and 83 percent of participants on that dose lost at least 15 percent of their body weight. In the type 2 diabetes trial, weight loss was smaller, as it usually is in people with diabetes. Phase 3 TRIUMPH trials began reporting from late 2025, with larger losses over longer treatment periods. Two cautions apply. There is no head-to-head trial against tirzepatide or semaglutide, so cross-trial comparisons mislead, since populations, durations and reporting methods differ. And the long-term questions (cardiovascular and kidney outcomes, weight regain after stopping, safety in older or frailer people) are still being measured, with a dedicated outcomes trial running for years yet.
Mostly gastrointestinal, dose-related and heaviest during escalation. Nausea, vomiting, diarrhoea and constipation were the most common adverse events in trials, and most were mild to moderate, but they tend to peak a day or two after each injection and after every step up in dose. Because exposure keeps building for weeks, a dose that felt fine in week one can feel very different in week four. The guide maps every side effect from common to serious, with first-line responses and clear triggers for medical evaluation: severe or persistent abdominal pain, signs of gallbladder problems, being unable to keep fluids down, and symptoms of dehydration all need a doctor. It is equally direct about who has not been adequately studied: pregnancy and breastfeeding, adolescents, frail older adults, advanced kidney disease, decompensated liver disease, active cancer, and anyone with prior pancreatitis or biliary disease.
Rapid weight loss always takes some lean mass with it, and on this class of drug the absolute loss can be large, even if the proportion that is lean is similar to dieting. Retatrutide is not a recomposition drug and it does not build muscle; it reduces intake and body weight. Four levers defend lean mass: adequate protein spread across the day, resistance training kept up rather than replaced with cardio, a rate of loss that is not too fast week after week, and sleep. Eating as little as possible is not the goal when appetite is suppressed; eating well while you can is. The Protein Calculator sets your protein floor, the Calorie & Macro Calculator keeps intake from dropping too low, and the Workout Planner Engine keeps resistance training in the week.
The full guide covers the triple-agonist science, the comparison with semaglutide and tirzepatide, pharmacokinetics, the physiology of appetite, gut and glucose, the full clinical trial map, what investigational trials actually studied, titration science, the side effect master table with troubleshooting, nutrition, muscle retention, supplements, interactions, stacking claims and a 30-question FAQ in detail. Download the PDF for the complete reference.
This page and the full guide are for educational purposes only. They are not medical advice, a prescription or a recommendation to use retatrutide. Retatrutide is an investigational drug that is not approved by any major regulator and is available only within clinical trials; products sold online as retatrutide are not the approved medicine and their contents cannot be verified. Any dosing described in the PDF reports what trials studied and is not a treatment recommendation. Do not start, stop or change any medication without a qualified clinician. This content is not for anyone under 18, pregnant or breastfeeding, or with a history of pancreatitis, gallbladder disease, advanced kidney disease or active cancer.
No. It is investigational everywhere, and Lilly has said it plans to file with the FDA in early 2027, so any product sold online now is not the approved medicine.
In the Phase 2 obesity trial, the highest dose produced about 24 percent average weight loss at 48 weeks, and Phase 3 trials reported larger losses over longer periods. Individual results vary widely, and long-term outcomes are still being measured.
Its trial numbers are higher, but no head-to-head trial has compared them, so cross-trial comparisons can mislead. It also adds a glucagon component, which makes it a different drug rather than a stronger version of the same one.
Some lean mass is lost with any large weight loss, roughly in proportion to the total. Adequate protein, resistance training and a steadier rate of loss protect most of it.
This guide is for educational purposes only and is not medical advice.
Newsletter
One email when a new guide, calculator or breakdown goes live. Nothing else.
